← Back
Data updated: Jul 17, 2026
DUTCH OPHTHALMIC
Pharma Pharmaceuticals
DUTCH OPHTHALMIC is a pharmaceutical company with 1 FDA-approved products.
2019
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
DUTCH OPHTHALMIC's Key Drugs
DUTCH OPHTHALMIC's core commercial portfolio centers on TISSUEBLUE — its most strategically important drugs approved in the last 15 years.
DUTCH OPHTHALMIC's Recent FDA Approvals
New NDA/BLA approvals for DUTCH OPHTHALMIC over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
DUTCH OPHTHALMIC's Therapeutic Areas
Disease areas where DUTCH OPHTHALMIC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
DUTCH OPHTHALMIC Pipeline Snapshot
Active clinical trials for DUTCH OPHTHALMIC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TISSUEBLUE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2019-12-20
- Latest
- 2025-04-04
- Applications
- 1